TradeFlare's AI research teams analysed CMPS on 6 market nights between May 21, 2026 and July 20, 2026. Each row is that night's verdict, the price that day, and how the price actually moved afterwards — wins and misses alike. Nothing is edited after the fact.
| Date | Verdict | Price | Target / stop | 5 days later | 20 days later | Why (that night) |
|---|---|---|---|---|---|---|
| July 20, 2026 | BUY | $12.35 | — / — | -3.4% | +17.6% | Positive Phase 3 trial data for COMP360. |
| July 17, 2026 | BUY | $12.43 | $14.64 / $10.37 | -8.8% | +8.9% | The bullish fundamental and sentiment outlook, coupled with the oversold technical signal, suggests a potential bounce that could play out over a few weeks. |
| June 17, 2026 | BUY | $11.49 | $12.30 / $8.67 | +13.7% | +3.4% | The current setup suggests a short-term bounce opportunity driven by sentiment and fundamental strength, with a longer-term outlook dependent on clinical trial progress. |
| June 12, 2026 | BUY | $11.41 | — / — | +4.5% | +10.8% | The current market and stock setup does not warrant a trade. |
| June 10, 2026 | BUY | $11.26 | — / — | +8.2% | +23.7% | Positive clinical trial results for COMP360. |
| May 21, 2026 | HOLD | $10.87 | — / — | +12.7% | +9.0% | Continued positive clinical trial data for COMP360. |
Prices are daily closes. "Days later" counts trading days from the close on the day of the call. A HOLD is not a recommendation to buy; only published signals are tracked with a target and stop on the public record. How the research works. Updated October 14, 2026. AI-generated research for educational purposes — it can be wrong and is not financial advice.